Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States

Antimicrob Agents Chemother. 2014;58(2):1243-7. doi: 10.1128/AAC.02112-13. Epub 2013 Dec 9.

Abstract

This study summarizes the linezolid susceptibility testing results for 7,429 Gram-positive pathogens from 60 U.S. sites collected during the 2012 sampling year for the LEADER Program. Linezolid showed potent activity when tested against 2,980 Staphylococcus aureus isolates, inhibiting all but 3 at ≤2 μg/ml. Similarly, linezolid showed coverage against 99.5% of enterococci, as well as for all streptococci tested. These results confirm a long record of linezolid activity against U.S. Gram-positive isolates since regulatory approval in 2000.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology*
  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Bacterial / genetics*
  • Enterococcus / drug effects*
  • Enterococcus / genetics
  • Enterococcus / isolation & purification
  • Epidemiological Monitoring
  • Gram-Positive Bacterial Infections / drug therapy
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Linezolid
  • Microbial Sensitivity Tests
  • Oxazolidinones / pharmacology*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / genetics
  • Staphylococcus aureus / isolation & purification
  • Streptococcus / drug effects*
  • Streptococcus / genetics
  • Streptococcus / isolation & purification
  • United States

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Linezolid